News

October 6, 2017October 6, 2017

AIRWISE Phase 4 Trial Assessing Various Combos of COPD Therapies Is Underway

The AIRWISE phase 4 clinical trial aiming to assess how commonly prescribed medicines may decrease the worsening of symptoms in chronic obstructive pulmonary disease (COPD) has begun enrolling the ... Read more

October 5, 2017October 5, 2017

Bevespi Aerosphere Progressing Toward Regulatory Approval for COPD in Europe, Asia

News

AstraZeneca’s Bevespi Aerosphere was shown to improve lung function in patients with moderate- to very severe-chronic obstructive pulmonary disease (COPD), in the latest PINNACLE 4 clinical trial. The promising ... Read more

October 3, 2017October 3, 2017

Stem Cells May Offset Damage Done by Smoking to Cells in Lungs, Early Study Says

News

Stem cells offer protective effects for damaged lung cells exposed to cigarette smoking by alleviating oxidative stress in mitochondria, a study shows. These results were also observed in mice ... Read more

September 28, 2017

Synairgen to Test SNG001 in Trial for COPD Exacerbations Caused by Viruses

News

Synairgen is moving from the treatment of respiratory viral infections in patients with asthma to those with chronic obstructive pulmonary disease (COPD) with its inhaled interferon beta investigative therapy SNG001. The ... Read more

September 28, 2017

Inhaled RPL554 Provides Optimal Delivery for COPD, Other Respiratory Illnesses, Trial Shows

News

Verona Pharma’s lead investigational medicine RPL554, engineered to treat patients with chronic obstructive pulmonary disease (COPD) and other respiratory disorders, was found to have an effective therapeutic profile when ... Read more

September 26, 2017September 26, 2017

Pulmatrix Issued Key US Patents for Inhaled Delivery System and PUR0200 for COPD

News

The U.S. Patent and Trademark Office (USPTO) issued two new patents requested by Pulmatrix – one for the expansion of its iSPERSE drug delivery technology and one for the expansion of protections ... Read more

September 21, 2017September 21, 2017

Phase 3 Trials Show GSK’s Nucala Can Reduce Exacerbations in Specific COPD Patients

News

Two Phase 3 clinical trials demonstrated that the antibody Nucala (mepolizumab) from GlaxoSmithKline has a moderate efficacy in the reduction of the rate of exacerbations in chronic obstructive pulmonary disease (COPD) ... Read more

September 20, 2017September 20, 2017

FDA Approves Triple Combination, Trelegy Ellipta, as Maintenance Therapy for COPD

News

The U.S. Food and Drug Administration has approved a triple combination treatment developed by GlaxoSmithKline as a maintenance therapy for chronic obstructive pulmonary disease. GSK collaborated with Innoviva on the COPD combo, which consists of fluticasone ... Read more

September 19, 2017September 22, 2017

Triple Combo Inhaler Trimbow More Effective than Utibron for COPD, Chiesi Trial Finds

News

Chiesi recently completed a long-term study showing that its extra-fine, fixed-dose, triple combination inhaler Trimbow is more effective than Utibron (indacaterol and glycopyrronium) as a therapy for chronic obstructive pulmonary disease (COPD). Trimbow ... Read more

September 16, 2017September 16, 2017

Once-a-day Triple Combo Inhaler for COPD Patients Favored for Approval in EU

News

A triple combination inhaler for people with moderate to severe adult chronic obstructive pulmonary disease (COPD) was recommended for approval and use across the European Union this week by CHMP, the ... Read more